4536 SANTEN PHARMACEUTICAL CO.,LTD. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4536

TSE Prime

SANTEN PHARMACEUTICAL CO.,LTD.

1,551.0

JPY

-5.5

(-0.35%)

Dec 5, 3:30 pm JST

10.03

USD

Dec 5, 1:30 am EST

Result

ー

PTS

outside of trading hours

ー

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2022	266,257	35,886	35,616	27,218	68.1	32	May 10, 2022	IFRS
Mar, 2023	279,037	-3,090	-5,799	-14,948	-38.6	32	May 11, 2023	IFRS
Mar, 2024	301,965	38,541	29,874	26,642	72.6	33	May 9, 2024	IFRS
Mar, 2025	300,004	46,880	47,481	36,256	104.0	36	May 13, 2025	IFRS
Mar, 2026 Guidance	294,000	44,000	ー	34,000	105.7	38	Aug 7, 2025	IFRS
YoY	-2.0%	-6.1%	－	-6.2%	+1.7%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2021	May 8, 2020	235,000	35,000	34,000	23,000	28	IFRS
	Apr 9, 2021	249,000	14,500	14,000	7,000	28	IFRS
Results	May 11, 2021	249,605	12,187	11,688	9,311	28	IFRS
Mar, 2022	May 11, 2021	Available in future release
Results	May 10, 2022
Mar, 2023	May 10, 2022
	Aug 4, 2022
	Nov 8, 2022
	Feb 7, 2023
	Apr 27, 2023
Results	May 11, 2023
Mar, 2024	May 11, 2023
	Sep 20, 2023
	Nov 7, 2023
	Feb 8, 2024
Results	May 9, 2024
Mar, 2025	May 9, 2024
	Aug 6, 2024
	Nov 7, 2024
	Feb 6, 2025
Results	May 13, 2025
Mar, 2026	May 13, 2025	294,000	44,000	33,500	34,000	38	IFRS
-	Aug 7, 2025	294,000	44,000	ー	34,000	38	IFRS

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2001	88,448	+5.8	Available in future release
Mar, 2002	88,966	+0.6
Mar, 2003	90,252	+1.4
Mar, 2004	89,857	-0.4
Mar, 2005	92,696	+3.2
Mar, 2006	98,397	+6.2
Mar, 2007	100,485	+2.1
Mar, 2008	103,394	+2.9
Mar, 2009	101,618	-1.7
Mar, 2010	110,594	+8.8
Mar, 2011	110,812	+0.2
Mar, 2012	114,416	+3.3
Mar, 2013	119,066	+4.1
Mar, 2014	146,260	+22.8
Mar, 2015	161,831	+10.6
Mar, 2016	195,291	+20.7
Mar, 2017	199,096	+1.9
Mar, 2018	224,942	+13.0
Mar, 2019	234,026	+4.0
Mar, 2020	241,555	+3.2
Mar, 2021	249,605	+3.3
Mar, 2022	266,257	+6.7
Mar, 2023	279,037	+4.8
Mar, 2024	301,965	+8.2
Mar, 2025	300,004	-0.6
Mar, 2026 Guidance	294,000	-2.0	44,000	-6.1	ー	-100.0	105.7	+1.6

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2024	301,965	38,541	12.8	8.88	6.22	0.70	72.6
Mar, 2025	300,004	46,880	15.6	12.24	8.58	0.71	104.0
Mar, 2026 Guidance	294,000	44,000	15.0	12.37	8.74	0.76	105.7

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	301,965	80,180	79,470	53,373	129.0
Fiscal Year	Mar, 2024	Mar, 2016	Mar, 2016	Mar, 2016	Mar, 2016

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2022	150,122	15,931	13,304	7,093	18.3	16	May 11, 2023	IFRS
Oct - Mar, 2023	156,159	13,442	5,799	7,362	20.1	17	May 9, 2024	IFRS
Oct - Mar, 2024	153,600	23,007	23,642	17,484	50.1	19	May 13, 2025	IFRS
Oct - Mar, 2025 Guidance	156,121	26,085	ー	20,060	62.4	19	Nov 6, 2025	IFRS
YoY	+1.6%	+13.4%	－	+14.7%	+24.4%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2023	-3,090	10,370	37,147	-26,777	-37,220	57,903	13.75	IFRS
Mar, 2024	38,541	66,504	72,649	-6,145	-34,031	94,582	21.71	IFRS
Mar, 2025	46,880	52,705	60,928	-8,223	-53,307	92,997	22.72	IFRS

Actual Performance and Financial Trends

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Sep, 2023	145,806	25,099	24,075	19,280	52.1	80.6	Nov 7, 2023	IFRS
Apr - Sep, 2024	146,404	23,873	23,839	18,772	52.9	50.2	Nov 7, 2024	IFRS
Apr - Sep, 2025	137,879	17,915	17,634	13,940	41.8	ー	Nov 6, 2025	IFRS
YoY	-5.8%	-25.0%	-26.0%	-25.7%	-21.0%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2023	77,027	11,058	9,484	7,333	19.9	14.4	Feb 8, 2024	IFRS
Jan - Mar, 2024	79,132	2,384	-3,685	29	0.1	3.0	May 9, 2024	IFRS
Apr - Jun, 2024	74,771	13,155	13,450	10,633	29.6	17.6	Aug 6, 2024	IFRS
Jul - Sep, 2024	71,633	10,718	10,389	8,139	22.9	15.0	Nov 7, 2024	IFRS
Oct - Dec, 2024	76,369	11,322	11,470	8,693	24.8	14.8	Feb 6, 2025	IFRS
Jan - Mar, 2025	77,231	11,685	12,172	8,791	25.2	15.1	May 13, 2025	IFRS
Apr - Jun, 2025	68,737	7,573	7,450	5,878	17.3	11.0	Aug 7, 2025	IFRS
Jul - Sep, 2025	69,142	10,342	10,184	8,062	24.2	15.0	Nov 6, 2025	IFRS
YoY	-3.5%	-3.5%	-2.0%	-0.9%	+5.3%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2020	62,881	-1.1	Available in future release
Jan - Mar, 2021	67,819	+14.5
Apr - Jun, 2021	64,986	+12.9
Jul - Sep, 2021	63,773	+4.0
Oct - Dec, 2021	67,042	+6.6
Jan - Mar, 2022	70,456	+3.9
Apr - Jun, 2022	65,533	+0.8
Jul - Sep, 2022	63,382	-0.6
Oct - Dec, 2022	70,871	+5.7
Jan - Mar, 2023	79,251	+12.5
Apr - Jun, 2023	72,389	+10.5
Jul - Sep, 2023	73,417	+15.8
Oct - Dec, 2023	77,027	+8.7
Jan - Mar, 2024	79,132	-0.2
Apr - Jun, 2024	74,771	+3.3
Jul - Sep, 2024	71,633	-2.4
Oct - Dec, 2024	76,369	-0.9
Jan - Mar, 2025	77,231	-2.4
Apr - Jun, 2025	68,737	-8.1
Jul - Sep, 2025	69,142	-3.5	10,342	-3.5	10,184	-2.0	24.2	+5.7

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	79,251	54,586	54,109	36,116	87.3
Fiscal Year	Mar, 2023	Sep, 2015	Sep, 2015	Sep, 2015	Sep, 2015

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2023	783.30	69.8	421,179	293,979	238,071	ー	May 11, 2023	IFRS
Mar, 2024	843.24	70.2	435,699	306,055	240,029	ー	May 9, 2024	IFRS
Mar, 2025	839.20	69.9	409,277	286,242	228,291	ー	May 13, 2025	IFRS
Apr - Sep, 2025	846.33	70.6	389,137	274,767	235,744	ー	Nov 6, 2025	IFRS

SANTEN PHARMACEUTICAL CO.,LTD.(4536) Financial Results